| Size | Price | Stock | Qty |
|---|---|---|---|
| 100g |
|
||
| Other Sizes |
Purity: ≥98%
| Targets |
PEG8000 does not have a specific biological target. Its function is as a pharmaceutical excipient and a tool in biochemical research. The polymer's effects are physicochemical, such as reducing the solubility of virus particles to facilitate precipitation, rather than through receptor or enzyme interactions.
|
|---|---|
| ln Vitro |
Chlorella virus FJ-1 was isolated in Fujian Province of China. It can be precipitated by polyethylene glycol(PEG8000) and the best condition if 7% PEG8000 and 4% NaCl. But the precipitation efficiency of PEG8000 is lower than that of ultracentrifugation [1].
In vitro, PEG8000 is used for the precipitation of bacteriophages and the isolation of plasmid DNA. It can also promote the enrichment and purification of virus particles by reducing their solubility in solution. The compound is also used in various biochemical assays as a crowding agent. |
| ln Vivo |
In vivo, PEG8000 is used as a pharmaceutical excipient in various formulations. FDA has approved PEGs for use as carriers or matrices in injectable, topical, rectal, and nasal preparations. The compound exhibits low toxicity and is generally well-tolerated.
|
| Enzyme Assay |
In vitro enzyme/receptor binding assays are not applicable to PEG8000, as it is not a bioactive compound that interacts with specific molecular targets. Its function in research is based on its physicochemical properties, such as its ability to precipitate macromolecules, rather than on enzyme inhibition or receptor binding.
|
| Cell Assay |
In vitro cellular assays for PEG8000 are not typically performed for its own biological activity. However, it may be used as a component in cell culture media or as a tool to study macromolecular crowding effects on cellular processes. The compound's biocompatibility and low toxicity are well established.
|
| Animal Protocol |
Aim: Although polyethylene glycol (PEG) is a neutral, biocompatible hydrophilic polymer recognized for its lack of interaction with biological barrier, its neurotoxicity has not been clearly identified in neurosurgery. This study is constructed to evaluate the possible neurotoxicity of a PEG hydrogel dural sealant.[2]
Material and methods: After a burrhole was opened in the left parietal bone of the twenty five Wistar albino rats, the dura mater and cerebral cortex were incised and the experimental material (activated polyethylene glycol and polyethylene imine) was sprayed into the burrhole. Then brain tissues were harvested for histopathological and biochemical studies at 72 hours to investigate the acute stage changes and on 15th day to evaluate the chronic stage changes.[2] Results: There were statistically significant differences among the groups regarding the comparison of the values of the PMNL cell infiltration grades, gliosis and congestion in both acute and chronic stages. However, the values of the MNL cell infiltration grades, edema and fibrin formation, lipid peroxidation levels of harvested brain tissues were similar in all groups.[2] Conclusion: Although this study did not present the detailed histopathological and biochemical evaluation results, it indicated that the application of the PEG-based hydrogel sealant was not associated with neurotoxicity, delayed healing, or degenerative changes.[2] In vivo animal studies for PEG8000 are generally related to its safety evaluation as an excipient. PEGs are known to have low toxicity and can be cleared intact from the body via the kidneys (for PEGs <30 kDa) or feces (for PEGs >20 kDa). Standard toxicological assessments confirm its safety for use in pharmaceutical products. |
| ADME/Pharmacokinetics |
PEG8000, with a molecular weight of 8000 Da, is primarily cleared via the kidneys. The polymer is not metabolized and is excreted intact. Its lack of immunogenicity contributes to its favorable pharmacokinetic profile. The compound's good water solubility facilitates its use in various formulations.
|
| Toxicity/Toxicokinetics |
PEG8000 exhibits low toxicity. It is non-toxic and non-irritating. FDA has approved PEGs for use in food, cosmetics, and pharmaceuticals. The compound's biocompatibility and lack of immunogenicity make it a safe choice for various applications.
|
| References |
[1]. Precipitation of chlorella virus FJ-1 by polyethylene glycol(PEG8000). Wei Sheng Wu Xue Bao. 2000 Oct;40(5):556-8.
[2]. Evaluation of the neurotoxicity of the polyethylene glycol hydrogel dural sealant. Turk Neurosurg. 2013;23(1):16-24. |
| Additional Infomation |
PEG8000 is a commonly used polymer in pharmaceutical and research applications. It is used as an excipient in various drug products and as a tool for phage precipitation and DNA isolation. The compound is known for its good water solubility, low toxicity, and biocompatibility.
|
| Molecular Formula |
(C2H4O)NH2O
|
|---|---|
| Molecular Weight |
8000
|
| CAS # |
25322-68-3
|
| Appearance |
White to off-white solid powder
|
| Density |
1.125
|
| Boiling Point |
250ºC
|
| Melting Point |
-65ºC
|
| Flash Point |
171ºC
|
| Vapour Pressure |
<0.01 mm Hg ( 20 °C)
|
| Index of Refraction |
1.458-1.461
|
| LogP |
0
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 0.1250 mL | 0.6250 mL | 1.2500 mL | |
| 5 mM | 0.0250 mL | 0.1250 mL | 0.2500 mL | |
| 10 mM | 0.0125 mL | 0.0625 mL | 0.1250 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
COA